[go: up one dir, main page]

PE20070378A1 - FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA - Google Patents

FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA

Info

Publication number
PE20070378A1
PE20070378A1 PE2006000998A PE2006000998A PE20070378A1 PE 20070378 A1 PE20070378 A1 PE 20070378A1 PE 2006000998 A PE2006000998 A PE 2006000998A PE 2006000998 A PE2006000998 A PE 2006000998A PE 20070378 A1 PE20070378 A1 PE 20070378A1
Authority
PE
Peru
Prior art keywords
cyclodextrin
factor
beta
inhibitor
formulation
Prior art date
Application number
PE2006000998A
Other languages
English (en)
Inventor
Munir N Nassar
Uday S Gogate
Timothy M Malloy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20070378A1 publication Critical patent/PE20070378A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UNA FORMULACION FARMACEUTICA INYECTABLE QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa Y UN AGENTE DE SOLUBILIZACION TAL COMO UNA BETA-CICLODEXTRINA SUSTITUIDA, DONDE EL INHIBIDOR DEL FACTOR Xa ES UN COMPUESTO PIRAZOLOPIRIDINA SUSTITUIDO CON R3, R4 Y R5, DONDE R3 ES H2N(C=O)-, ALQUIL-SO2-, ENTRE OTROS; R4 ES ALCOXI Y HALOGENO; R5 ES UN HETEROCICLO DONDE Q ES UN ANILLO MONOCICLICO DE 6 MIEMBROS EN DONDE 0, 1 O2 ENLACES DOBLES ESTAN PRESENTES DENTRO DEL ANILLO Y EL ANILLO SE SUSTITUYE CON 0, 1 O 2 GRUPOS R5a QUE SE SELECCIONA DE H, O O ALQUILO Y Q1 ES C=O. ASIMISMO, LA FORMULACION PUEDE COMPRENDER UN AMORTIGUADOR TAL COMO ACIDO TARTARICO, ACIDO CITRICO, ACIDO CLORHIDRICO, ENTRE OTROS. EL INHIBIDOR DEL FACTOR Xa SE SELECCIONA DE APIXABAN O RAZAXABAN Y LA BETA-CICLODEXTRINA SUSTITUIDA SE SELECCIONA DE SULFOBUTIL ETER BETA-CICLODEXTRINA (SBE-CD) O HIDROXIPROPIL BETA-CICLODEXTRINA (HPB-CD). DICHA FORMULACION ES UTIL PARA PREVENIR O TRATAR TROMBOSIS VENOSA, TROMBOSIS DE VENA PROFUNDA Y SINDROME CORORNARIO AGUDO
PE2006000998A 2005-08-17 2006-08-17 FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA PE20070378A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70907705P 2005-08-17 2005-08-17
US11/464,519 US20070191306A1 (en) 2005-08-17 2006-08-15 FACTOR Xa INHIBITOR FORMULATION AND METHOD

Publications (1)

Publication Number Publication Date
PE20070378A1 true PE20070378A1 (es) 2007-05-04

Family

ID=37654897

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006000998A PE20070378A1 (es) 2005-08-17 2006-08-17 FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA

Country Status (10)

Country Link
US (2) US20070191306A1 (es)
EP (1) EP1924291A2 (es)
JP (1) JP2009504746A (es)
AR (1) AR055377A1 (es)
BR (1) BRPI0614827A2 (es)
CA (1) CA2619214A1 (es)
MX (1) MX2008002057A (es)
PE (1) PE20070378A1 (es)
TW (1) TW200800270A (es)
WO (1) WO2007022165A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2900243T3 (es) 2008-10-22 2022-03-16 Array Biopharma Inc Compuestos de pirazolo[1,5-a]pirimidina sustituidos como inhibidores de trk quinasa
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
JP5846647B2 (ja) 2010-02-25 2016-01-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ アピキサバン製剤
CN110917130A (zh) * 2012-06-27 2020-03-27 武田药品工业株式会社 用盐稳定的胺和有机酸的液体制剂
CN104736142B (zh) * 2012-09-26 2020-03-03 百时美-施贵宝控股爱尔兰无限公司 阿哌沙班液体制剂
CN104650072B (zh) * 2013-11-18 2016-03-16 成都苑东生物制药股份有限公司 一种吡啶类衍生物
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
HUE068971T2 (hu) 2016-04-04 2025-02-28 Loxo Oncology Inc (S)-N-(5-((R)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-A]pirimidin-3-il) -3-hidroxipirrolidin-1-karboxamid folyékony készítményei
PT3800189T (pt) 2016-05-18 2023-07-27 Array Biopharma Inc Preparação de (s)-n-(5-((r)-2-(2,5- difluoropenil)pirrolidin-1-il)pirazolo[1,5-a]pirimidin-3- il)-3-hidroxipirrolidina-1-carboxamida
CN115715770B (zh) * 2021-08-24 2024-01-26 新领医药技术(深圳)有限公司 阿哌沙班透皮贴剂及其制备方法
WO2023072967A1 (en) 2021-10-27 2023-05-04 Pharma-Data S.A. Apixaban suspension and preparation method
NL2029536B1 (en) 2021-10-27 2023-05-26 Pharma Data S A Apixaban suspension and preparation method
WO2026003874A1 (en) * 2024-06-28 2026-01-02 Cipla Limited Injectable compositions of apixaban

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US4745105A (en) * 1986-08-20 1988-05-17 Griffin Charles C Low molecular weight heparin derivatives with improved permeability
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
UA57734C2 (uk) * 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
JPH10194996A (ja) * 1996-12-25 1998-07-28 Janssen Pharmaceut Nv アシル化シクロデキストリン含有製薬組成物
US6339099B1 (en) * 1997-06-20 2002-01-15 Dupont Pharmaceuticals Company Guanidine mimics as factor Xa inhibitors
FR2773801B1 (fr) * 1998-01-19 2000-05-12 Sanofi Sa Nouveaux pentasaccharides, procedes pour leurs preparations et compositions pharmaceutiques les contenant
BR0013926A (pt) * 1999-09-13 2002-07-23 Dimensional Pharm Inc Inibidores de serina protease de azacicloalcanona
TWI331526B (en) * 2001-09-21 2010-10-11 Bristol Myers Squibb Pharma Co Lactam-containing compounds and derivatives thereof as factor xa inhibitors
CN101357914A (zh) * 2001-09-21 2009-02-04 百时美施贵宝公司 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂

Also Published As

Publication number Publication date
WO2007022165A3 (en) 2007-08-23
MX2008002057A (es) 2008-04-16
EP1924291A2 (en) 2008-05-28
JP2009504746A (ja) 2009-02-05
WO2007022165A2 (en) 2007-02-22
AR055377A1 (es) 2007-08-22
WO2007022165B1 (en) 2007-10-18
CA2619214A1 (en) 2007-02-22
BRPI0614827A2 (pt) 2011-04-19
TW200800270A (en) 2008-01-01
US20090291913A1 (en) 2009-11-26
US20070191306A1 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
PE20070378A1 (es) FORMULACION DE INHIBIDOR DE LA FACTOR Xa Y B-CICLODEXTRINA
PE20220017A1 (es) Inhibidores del kcnt1 y metodos de uso
PE20190624A1 (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostericos de shp2
PE20121091A1 (es) Derivados de purina o deazapurina utiles en el tratamiento de (inter alia) infecciones virales
CR8047A (es) Procedimiento de tratamiento de la arterosclerosis, dislipidemias y afecciones relacionadas y composiciones farmaceuticas
CY1115289T1 (el) Μεθοδοι αγωγης εναντι ασθενειας που σχετιζεται με φλεγμονη
BR112022013150A2 (pt) Derivado da insulina
ECSP088208A (es) Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c
AR034422A1 (es) Una composicion de resina de polipropileno que contiene un derivado de acido trimesico, un metodo para proveer una resina con un valor de niebla menor de 62%, un uso del derivado de acido trimesico como agente reductor de niebla, mezclas que contienen los derivados de acidos trimesicos, composicione
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
ECSP045073A (es) Nuevos derivados de piperazina
PE20191496A1 (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
MX385600B (es) Pirazolopirimidinas sustituidas como activadores de la glucocerebrosidasa.
ECSP088239A (es) Composición de liberación de fármaco sostenida
PE20060003A1 (es) Formulacion farmaceutica polimerica para moldear por inyeccion
DE60305052D1 (de) Thienopyrrolyl und furanopyrrolyl verbindungen und deren verwendung als histamin h4 rezeptor liganden
UY31305A1 (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
ATE418548T1 (de) Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten
CL2022002148A1 (es) Inhibidores heterocíclicos de pad4
AR066962A1 (es) Compuesto heterociclico fusionado
NZ608738A (en) A sulfated polysaccharide compound and the preparation and use thereof
JOP20200265A1 (ar) متقارنات ببتيد تيروسين-تيروسين حلقي مرتبطة بببتيد اندماجي شبيه بالجلوكاجون 1 (glp-1) واستخداماتها
PE20061015A1 (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas
PE20090357A1 (es) Compuestos heterociclicos con actividad sobre los receptores muscarinicos m3

Legal Events

Date Code Title Description
FC Refusal